ESTRATÉGIAS PARA A OTIMIZAÇÃO DO USO DA VANCOMICINA NA TERAPIA DE INFECÇÕES CAUSADAS POR Staphylococcus aureus RESISTENTES À METICILINA

Resumen

Infecções por Staphylococcus aureus resistentes a meticilina (MRSA) são frequentes e possuem elevados níveis de mortalidade, principalmente em pacientes hospitalizados. A vancomicina está entre as drogas de escolha para o tratamento de tais infecções. Tendo em vista as limitações terapêuticas e o surgimento de resistência faz-se necessário estratégias para otimizar a farmacocinética e a farmacodinâmica da vancomicina. O objetivo deste trabalho foi estudar estratégias terapêuticas para otimizar o tratamento com vancomicina. A AUC/MIC>400 é uma medida proposta para otimizar a efetividade do tratamento do MRSA, no entanto esta estratégia não é rotina na prática clínica em virtude das limitações técnicas. A concentração mínima entre 16-20 mg/L e a máxima de 80 mg/L é geralmente padronizada para garantir a eficácia do tratamento e minimizar os efeitos adversos. Além disso, a fim de reduzir a nefrotoxicidade causada pela vancomicina propõem-se o regime de infusão continua que favorece a eficácia do tratamento.

Descargas

La descarga de datos todavía no está disponible.

Metrics

Cargando métricas ...

Citas

ÁLVAREZ, R. et al. Vancomycin: Optimizing Its Clinical USe. Antimicrobial Agents and Chemotherapy, v. 60, n. 5, p. 2601–2609, 2016.
AMERICAN THORACIC SOCIETY; INFECTIOUS DISEASES SOCIETY OF AMERICA. Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. American Journal of Respiratory and Critical Care Medicine, v. 171, n. 4, p. 388–416, 15 fev. 2005.
ANTONANZAS, F.; LOZANO, C.; TORRES, C. Economic Features of Antibiotic Resistance: The Case of Methicillin-Resistant Staphylococcus aureus. PharmacoEconomics, v. 33, n. 4, p. 285–325, 2 abr. 2015.
ARIAS, C. A.; COURVALIN, P.; REYNOLDS, P. E. vanC cluster of vancomycin-resistant Enterococcus gallinarum BM4174. Antimicrobial agents and chemotherapy, v. 44, n. 6, p. 1660–6, 1 jun. 2000.
BARCELÓ-VIDAL, J.; RODRÍGUEZ-GARCÍA, E.; GRAU, S. Extremely high levels of vancomycin can cause severe renal toxicity. Infection and drug resistance, v. 11, p. 1027–1030, 2018.
BOSSO, J. A. et al. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrobial agents and chemotherapy, v. 55, n. 12, p. 5475–9, dez. 2011.
BRUNTON, L. L.; CHABNER, B. A.; KNOLLMANN, B. C. Goodman & Gilman: As Bases Farmacológicas da Terapêutica. 12a edição ed. Rio de Janeiro: McGraw-Hil, 2012.
CHAMBERS, H. F.; DELEO, F. R. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nature Reviews Microbiology, v. 7, n. 9, p. 629–641, 1 set. 2009.
CRASS, R. L. et al. Dosing vancomycin in the super obese: less is more. Journal of Antimicrobial Chemotherapy, v. 73, n. 11, p. 3081–3086, 1 nov. 2018.
DIEKEMA, D. J. et al. Survey of Infections Due to Staphylococcus Species: Frequency of Occurrence and Antimicrobial Susceptibility of Isolates Collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clinical Infectious Diseases, v. 32, n. s2, p. S114–S132, 15 maio 2001.
FEWEL, N. P. Comparison of open-access vancomycin dosing websites. Journal of Clinical Pharmacy and Therapeutics, v. 42, n. 2, p. 128–131, abr. 2017.
FILIPPONE, E.; KRAFT, W.; FARBER, J. The Nephrotoxicity of Vancomycin. Clinical Pharmacology & Therapeutics, v. 102, n. 3, p. 459–469, 1 set. 2017.
GOUDARZI, M. et al. Molecular Characterization of Methicillin Resistant Staphylococcus aureus Strains Isolated from Intensive Care Units in Iran: ST22-SCCmec IV/t790 Emerges as the Major Clone. PloS one, v. 11, n. 5, p. e0155529, 2016.
GUPTA, A.; BIYANI, M.; KHAIRA, A. Vancomycin nephrotoxicity: myths and facts. The Netherlands journal of medicine, v. 69, n. 9, p. 379–83, set. 2011.
HANRAHAN, T. et al. Vancomycin-associated nephrotoxicity: A meta-analysis of administration by continuous versus intermittent infusion. International Journal of Antimicrobial Agents, v. 46, n. 3, p. 249–253, set. 2015.
HAO, J.-J.; CHEN, H.; ZHOU, J.-X. Continuous versus intermittent infusion of vancomycin in adult patients: A systematic review and meta-analysis. International Journal of Antimicrobial Agents, v. 47, n. 1, p. 28–35, jan. 2016.
HUTSCHALA, D. et al. Influence of Vancomycin on Renal Function in Critically Ill Patients after Cardiac Surgery. Anesthesiology, v. 111, n. 2, p. 356–365, 1 ago. 2009.
JEFFRES, M. N. The Whole Price of Vancomycin: Toxicities, Troughs, and Time. Drugs, v. 77, n. 11, p. 1143–1154, 1 jul. 2017.
KATAYAMA, Y.; ITO, T.; HIRAMATSU, K. A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrobial agents and chemotherapy, v. 44, n. 6, p. 1549–55, 1 jun. 2000.
KIRBY, W. M. EXTRACTION OF A HIGHLY POTENT PENICILLIN INACTIVATOR FROM PENICILLIN RESISTANT STAPHYLOCOCCI. Science (New York, N.Y.), v. 99, n. 2579, p. 452–3, 2 jun. 1944.
LIMA, M. F. P. et al. Staphylococcus aureus E AS INFECÇÕES HOSPITALARES – REVISÃO DE LITERATURA. REVISTA UNINGÁ REVIEW, v. 21, n. 1, 17 jan. 2018.
LINDSAY, J. A.; HOLDEN, M. T. G. Staphylococcus aureus: superbug, super genome? Trends in Microbiology, v. 12, n. 8, p. 378–385, 1 ago. 2004.
LIU, P. et al. Clinical outcomes of linezolid and vancomycin in patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus stratified by baseline renal function: a retrospective, cohort analysis. BMC nephrology, v. 18, n. 1, p. 168, 22 maio 2017.
LODISE, T. P. et al. Relationship between Initial Vancomycin Concentration‐Time Profile and Nephrotoxicity among Hospitalized Patients. Clinical Infectious Diseases, v. 49, n. 4, p. 507–514, 15 ago. 2009.
MARTINEZ, M. N.; PAPICH, M. G.; DRUSANO, G. L. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. Antimicrobial agents and chemotherapy, v. 56, n. 6, p. 2795–805, jun. 2012.
MEHTA, R. L. et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Critical care (London, England), v. 11, n. 2, p. R31, 2007.
MOISE-BRODER, P. A. et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clinical pharmacokinetics, v. 43, n. 13, p. 925–42, 2004.
NEELY, M. N. et al. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrobial agents and chemotherapy, v. 58, n. 1, p. 309–16, 1 jan. 2014.
PAZHAYATTIL, G. S.; SHIRALI, A. C. Drug-induced impairment of renal function. International journal of nephrology and renovascular disease, v. 7, p. 457–68, 2014.
PEREZ, L. R. R.; D’AZEVEDO, P. A. Clonal types and antimicrobial resistance profiles of methicillin-resistant Staphylococcus aureus isolates from hospitals in south Brazil. Revista do Instituto de Medicina Tropical de São Paulo, v. 50, n. 3, p. 135–137, jun. 2008.
PRYBYLSKI, J. P. Vancomycin Trough Concentration as a Predictor of Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: A Meta-analysis of Observational Studies. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, v. 35, n. 10, p. 889–898, out. 2015.
RAMMELKAMP, C. H.; MAXON, T. Resistance of Staphylococcus aureus to the Action of Penicillin. Experimental Biology and Medicine, v. 51, n. 3, p. 386–389, 1 dez. 1942.
RYBAK, M. J. The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin. Clinical Infectious Diseases, v. 42, n. Supplement 1, p. S35–S39, 2006.
RYBAK, M. J. et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy, v. 29, n. 11, p. 1275–9, nov. 2009.
SIDDIQUI, A. H.; WHITTEN, R. A. Methicillin Resistant Staphylococcus Aureus (MRSA). [s.l.] StatPearls Publishing, 2018.
SONG, K.-H. et al. Inoculum effect of methicillin-susceptible Staphylococcus aureus against broad-spectrum beta-lactam antibiotics. European Journal of Clinical Microbiology & Infectious Diseases, v. 38, n. 1, p. 67–74, 30 jan. 2019.
SPATENKOVA, V. et al. Low incidence of multidrug-resistant bacteria and nosocomial infection due to a preventive multimodal nosocomial infection control: a 10-year single centre prospective cohort study in neurocritical care. BMC neurology, v. 18, n. 1, p. 23, 7 mar. 2018.
STEINKRAUS, G.; WHITE, R.; FRIEDRICH, L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001 05. Journal of Antimicrobial Chemotherapy, v. 60, n. 4, p. 788–794, 10 jul. 2007.
STOKES, M. B. Vancomycin in the Kidney-A Novel Cast Nephropathy. Journal of the American Society of Nephrology : JASN, v. 28, n. 6, p. 1669–1670, jun. 2017.
TAFELSKI, S. et al. Observational clinical study on the effects of different dosing regimens on vancomycin target levels in critically ill patients: Continuous versus intermittent application. Journal of Infection and Public Health, v. 8, n. 4, p. 355–363, jul. 2015.
VAN HAL, S. J.; LODISE, T. P.; PATERSON, D. L. The Clinical Significance of Vancomycin Minimum Inhibitory Concentration in Staphylococcus aureus Infections: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, v. 54, n. 6, p. 755–771, 15 mar. 2012.
WYSOCKI, M. et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrobial agents and chemotherapy, v. 45, n. 9, p. 2460–7, set. 2001.
YE, Z.-K.; TANG, H.-L.; ZHAI, S.-D. Benefits of Therapeutic Drug Monitoring of Vancomycin: A Systematic Review and Meta-Analysis. PLoS ONE, v. 8, n. 10, p. e77169, 18 out. 2013.
YOU, A. S. et al. The Daniel K. Inouye College of Pharmacy Scripts: The Effects of Vancomycin Use and De-escalation in Patients Hospitalized with Pneumonia. Hawai’i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health, v. 77, n. 10, p. 261–267, out. 2018.
ZAMONER, W. et al. Vancomycin Dosing, Monitoring and Toxicity: Critical review of the clinical practice. Clinical and Experimental Pharmacology and Physiology, 9 jan. 2019.
ZHU, L.-L.; ZHOU, Q. Optimal infusion rate in antimicrobial therapy explosion of evidence in the last five years. Infection and drug resistance, v. 11, p. 1105–1117, 2018.
Publicado
2022-04-16
Cómo citar
1.
Casagrande L, Oliveira Bernardo CC de, Pastre MJ, Caparroz Assef SM. ESTRATÉGIAS PARA A OTIMIZAÇÃO DO USO DA VANCOMICINA NA TERAPIA DE INFECÇÕES CAUSADAS POR Staphylococcus aureus RESISTENTES À METICILINA. arqmudi [Internet]. 16 de abril de 2022 [citado 11 de septiembre de 2025];26(1):131-42. Disponible en: https://periodicos.uem.br/ojs/index.php/ArqMudi/article/view/62132
Sección
Artigo de Revisão em Ciências, Biologia e Biodiversidade